- Unilever commercial production of Lux soap featuring Solazyme algal oil. Last week, our partner Unilever announced that it has incorporated our sustainable algal oil into one of Unilever’s premier soap brands, Lux. The soap has been on store shelves in Brazil since early March.
- Commercialization progress at Clinton/Galva continues. Since late February Solazyme has doubled the number of customers purchasing ingredients manufactured at the Clinton/Galva facilities. Additionally, the Company is filling repeat orders, demonstrating strong progress in building trust and reliability of supply.
- Encapso™ lubricants launched in oil field services market. Solazyme’s first-of-its-kind encapsulated lubricant, Encapso TM, was launched into the oil field services market in March. Solazyme is working with multiple drilling operators and customers, including some repeat end customers, to rapidly expand commercial use and testing. Encapso™ lubricants have been used in about 20 wells to date, a 50% increase in well-count in just a few weeks, and has already been used in six basins.
- Algenist® launched in Nordstrom stores. In April, Solazyme reported that its award-winning anti-aging skin care brand, Algenist ®, is available for sale in select Nordstrom locations nationwide and on the retailer’s website. The Algenist ® line is featured as part of Nordstrom’s “Advanced Skincare” category.
- Raised $202.8 million in hybrid financing. On April 1, 2014, Solazyme announced the closing of its sale of 5,750,000 shares of its common stock, and $149.5 million aggregate principal amount of 5.00% Convertible Senior Subordinated Notes due 2019. Aggregate estimated net proceeds from the hybrid offering were $202.8 million.
Solazyme ® , Algenist ® , and the Solazyme logo are registered trademarks of Solazyme, Inc.Non-GAAP Financial Measures This press release includes the following financial measure defined as a “non-GAAP financial measure” by the Securities and Exchange Commission: non-GAAP net loss. This measure may be different from non-GAAP financial measures used by other companies. The presentation of this financial information, which is not prepared under any comprehensive set of accounting rules or principles, is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with generally accepted accounting principles. For a reconciliation of this non-GAAP financial measure to the nearest comparable GAAP measure, see “Reconciliation of GAAP to Non-GAAP Basic Net-Loss Per Share” included in the tables to this press release. This non-GAAP measure is provided to enhance investors’ overall understanding of Solazyme’s current financial performance and Solazyme’s prospects for the future. Specifically, Solazyme believes the non-GAAP measure provides useful information to both management and investors by excluding certain expenses that may not be indicative of its core operating results and business outlook. For its internal budgeting process, Solazyme’s management uses financial measures that do not include stock-based compensation expense or special expenses such as non-cash gains or losses due to warrant revaluations. In addition to the corresponding GAAP measures, Solazyme’s management also uses the foregoing non-GAAP measure in reviewing the financial results of Solazyme. Solazyme excludes stock-based compensation expenses and special non-cash charges from its non-GAAP measures primarily because they are non-cash expenses that management does not believe are reflective of ongoing operating results. Forward Looking Statements This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about Solazyme, including statements that involve risks and uncertainties concerning: its commercialization and production plans and commercialization timetable for its products; the timing of commercial product production; the commissioning of equipment and the ramping up of facilities; the timetable for bringing facilities online; meeting commercialization and technology targets; and Solazyme’s ability to maintain its relationships with its partners. When used in this press release, the words “will”, “expects”, “intends” and other similar expressions and any other statements that are not historical facts are intended to identify those assertions as forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any such statement may be influenced by a variety of factors, many of which are beyond the control of Solazyme, that could cause actual outcomes and results to be materially different from those projected, described, expressed or implied in this press release due to a number of risks and uncertainties. Potential risks and uncertainties include, among others: Solazyme’s limited operating history; its limited history in commercializing products; implementation risk in deploying new technologies; its limited experience in constructing, ramping up and operating commercial manufacturing facilities; its ability to sell its products at a profit; delays related to construction, start-up and ramp-up of production facilities; its ability to manage operational costs at production facilities; its ability to enter into and maintain strategic collaborations; its ability to obtain requisite regulatory approvals; and its access, on favorable terms, to any required financing. Accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of Solazyme.
In addition, please refer to the documents that Solazyme, Inc. files with the Securities and Exchange Commission, including its Annual Report on Form 10-K, as updated from time to time, for a discussion of these and other risks. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this press release. Solazyme is not under any duty to update any of the information in this press release.
|CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS|
|In thousands, except per share amounts|
|Three Months Ended March 31,|
|Research and development programs||$||5,043||$||2,680|
|Costs and operating expenses (1)|
|Cost of product revenue||3,390||1,454|
|Research and development||20,835||13,720|
|Sales, general and administrative||20,607||14,866|
|Total costs and operating expenses||44,832||30,040|
|Loss from operations||(32,441||)||(23,360||)|
|Other income (expense) (2)|
|Interest and other income (expense), net||(1,112||)||(1,523||)|
|Loss from equity method investment||(3,834||)||(959||)|
|Gain from change in fair value of warrant liability||688||54|
|Gain (loss) from change in fair value of derivative liability||2,018||(737||)|
|Total other income (expense)||(2,240||)||(3,165||)|
|Net loss per share, basic and diluted||$||(0.50||)||$||(0.43||)|
|Weighted average number of common shares used in loss per share computation, basic and diluted||69,213||61,543|
|RECONCILIATION OF GAAP TO NON-GAAP BASIC NET LOSS PER SHARE|
|In thousands, except per share amounts|
|Three Months Ended March 31,|
|Gain from change in fair value of warrant liability||(688||)||(54||)|
|(Gain) loss from change in fair value of derivative liability||(2,018||)||737|
|(1) Operating expenses include stock-based compensation expense as follows:|
|Research and development||1,820||1,089|
|Sales, general and administrative||4,789||2,916|
|Total stock-based compensation expense||6,609||4,005|
|(2) Other income (expense) includes costs as follows:|
|Amortization of debt discount and issuance costs||250||335|
|Net loss (non-GAAP)||$||(30,528||)||$||(21,502||)|
|Basic and diluted loss per share (GAAP)||$||(0.50||)||$||(0.43||)|
|Gain from change in fair value of warrant liability||(0.01||)||-|
|(Gain) loss from change in fair value of derivative liability||(0.03||)||0.01|
|Stock-based compensation expense||0.10||0.07|
|Amortization of debt discount and issuance costs||-||-|
|Net loss per share (non-GAAP)||$||(0.44||)||$||(0.35||)|
|CONDENSED CONSOLIDATED BALANCE SHEETS|
|March 31,||December 31,|
|Cash, cash equivalents and marketable securities||$||133,154||$||167,521|
|Other current assets||26,602||24,296|
|Total current assets||159,756||191,817|
|Property, plant and equipment - net||39,146||40,089|
|Liabilities and stockholders' equity|
|Current portion of long-term debt||$||55||$||65|
|Other current liabilities||20,352||25,229|
|Total current liabilities||20,407||25,294|
|Total stockholders' equity||120,566||138,948|
|Total liabilities and stockholders' equity||$||230,520||$||258,705|